Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Recurrence Patterns in Early-Stage HR+ Breast Cancer

August 12th 2022

Drs Mark Pegram and Lee Schwartzberg examine late recurrence patterns in patients with HR+ breast cancer.

Updated Guidelines for the Management of HR+ Breast Cancer

August 12th 2022

Experts highlight some important and surprising updates in the ASCO guidelines for the management of HR+ breast cancer.

FDA Grants Priority Review to Elacestrant for ER+/HER2- Advanced or Metastatic Breast Cancer

August 11th 2022

The FDA has granted priority review to a new drug application seeking the approval of elacestrant for use in patients with estrogen receptor–positive/HER2-negative advanced or metastatic breast cancer.

NCCN Elevates Sacituzumab Govitecan-Hziy to Preferred Recommendations in Metastatic Breast Cancer

August 10th 2022

Sacituzumab govitecan-hziy is now a category 1 preferred recommendation in triple-negative breast cancer and a category 2A preferred recommendation in HR-positive/HER2-negative disease.

Utilizing Brain MRI to Inform Treatment for HER2+ Metastatic Breast Cancer

August 10th 2022

A brief review of the value of using brain MRI to help determine treatment approaches for patients with HER2+ metastatic breast cancer.

KEYNOTE-522: Neoadjuvant Pembrolizumab + CT Followed by Adjuvant Pembrolizumab in TNBC

August 10th 2022

Expert perspectives on the KEYNOTE-522 clinical trial, which utilized adjuvant pembrolizumab following neoadjuvant pembrolizumab plus chemotherapy in TNBC.

ADCs in HR+/HER2- Advanced BC: Results From TROPICS-02 and DESTINY-Breast04

August 8th 2022

Centering discussion on the TROPICS-02 and DESTINY-Breast04 trials, panelists consider the advent of antibody drug conjugates in relapsed/refractory HR+ breast cancer.

Novel Treatment Strategies for HER2-Low Breast Cancer

August 8th 2022

Comprehensive insight on the novel treatment strategies available for patients diagnosed with HER2-low breast cancer.

Establishing the Paradigm of HER2-Low Breast Cancer

August 8th 2022

Expert perspectives on the advent of HER2-low disease and how it has been historically managed since its emergence as a subset of breast cancer.

Second-Line Use of CDK4/6 Inhibitors in HR+ Breast Cancer

August 8th 2022

Shared insight on the potential role of CDK4/6 inhibitors in the second-line setting of relapsed/refractory HR+/HER2- breast cancer.

Measuring Ki-67 Levels to Inform HR+ Breast Cancer Treatment

August 5th 2022

Lee Schwartzberg, MD, FACP, explains how Ki-67 is measured and used to inform management strategies for HR+ breast cancer at his clinical practice.

The Evolution of Early-Stage HR+ Breast Cancer Management

August 5th 2022

Lee Schwartzberg, MD, FACP, and Mark Pegram, MD, discuss how the management of early-stage HR+ breast cancer has changed over time.

FDA Approves Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-Low Breast Cancer

August 5th 2022

The FDA has approved fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of patients with unresectable or metastatic HER2-low breast cancer.

Gradishar Stresses the Importance of Accurately Defining Breast Cancer Subtypes

August 4th 2022

Dr Gradishar emphasizes the importance of defining metastatic breast cancer subtypes, the implications of molecular testing on treatment decisions, and the need for comprehensive patient-provider communication about therapeutic options and clinical trial opportunities throughout the course of disease.

EU Approves Adjuvant Olaparib for BRCA-Mutated, HER2-Negative Early Breast Cancer

August 4th 2022

The European Commission has approved olaparib as a single agent or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutated, HER2-negative, high-risk early breast cancer.

Adjuvant Abemaciclib in High-Risk HR+/HER2-, Node+ BC: The monarchE Trial

August 3rd 2022

Focusing on high-risk HR+/HER2- breast cancer, key opinion leaders review data with adjuvant abemaciclib from the monarchE clinical trial.

Adjuvant Olaparib in High-Risk gBRCA1/2 Mutated BC: The OlympiA Trial

August 3rd 2022

Comprehensive insight on trial data from OlympiA, which utilized adjuvant olaparib therapy in patients with gBRCA1/2 mutated breast cancer.

FDA Grants Fast Track Designation to OP-1250 in ER+/HER2- Metastatic Breast Cancer

August 2nd 2022

The FDA has granted a fast track designation to OP-1250 for the treatment of patients with ER-positive, HER2- metastatic breast cancer who have progressed following at least 1 line of endocrine therapy with at least 1 line administered in combination with a CDK4/6 inhibitor.

Practical Advice on the Management of TNBC

August 2nd 2022

Before closing out their conversation on metastatic triple-negative breast cancer, expert oncologists share a few clinical pearls on optimizing TNBC management.

Addressing Unmet Needs in the Management of TNBC

August 2nd 2022

Perspectives on the most prominent unmet needs in metastatic triple-negative breast cancer and how these may be addressed with future clinical trials.